BIOCORP Announces Initiation of Coverage by Gilbert Dupont
22 Giugno 2020 - 8:30AM
Business Wire
Coverage initiated with “Buy“ rating and €26,90
price target, based on promising outlooks in the market for
connected medical devices.
Regulatory News:
BIOCORP (FR0012788065 - ALCOR / Eligible PEA PME), a French
company specialized in the development and manufacturing of medical
devices and smart drug delivery systems, announces today that the
brokerage firm Gilbert Dupont has initiated analyst coverage of
BIOCORP with “Buy “ rating and €26,90 price target.
The detailed note is available in the shareholders' area on the
company's website
(https://biocorpsys.com/investisseurs/espace-actionnaires/).
Gilbert Dupont joins Bryan Garnier, whose analyst also initiated
coverage on the company with a “buy “ rating in April 2020.
All reports on BIOCORP prepared by analysts represent the views
of those analysts and not necessarily those of BIOCORP. BIOCORP is
not responsible for the content, accuracy, or timing of analyst
reports.
This information does not constitute an offer to sell or
subscribe, or the solicitation of an order to buy or subscribe for
securities in France, Europe, the US or any other country.
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture
of medical devices and delivery systems, BIOCORP has today acquired
a leading position in the connected medical device market thanks to
Mallya. This intelligent sensor for insulin injection pens allows
reliable monitoring of injected doses and thus offers better
compliance in the treatment of diabetics. Available for sale from
2020, Mallya spearheads BIOCORP's product portfolio of innovative
connected solutions. The company has 54 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 –
ALCOR).
For more information, please visit www.biocorpsys.com.
Follow us on Twitter @BIOCORPSystems
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200621005028/en/
BIOCORP CONTACTS Jacques Gardette Chairman of the Board
investisseurs@biocorp.fr Éric Dessertenne Chief Executive
Officer
Sylvaine Dessard Marketing & Communication Director
rp@biocorp.fr + 33 (0)6 88 69 72 85
ULYSSE COMMUNICATION CONTACTS Bruno ARABIAN
barabian@ulysse-communication.com +33 (0)6 87 88 46 26
Nicolas DANIELS ndaniels@ulysse-communication.com +33 (0)6 63 66
59 22
Grafico Azioni Biocorp (EU:ALCOR)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Biocorp (EU:ALCOR)
Storico
Da Apr 2023 a Apr 2024